Gapping up
In reaction to strong earnings/guidance:
- NAVI +9.7%, HCA +6.5%, CALX +6.4%, FMBI +5.9%, AIR +5.3%, TER +4.5%, OLLI +4.5% (guides JulQ revs well above consensus), BBY +4.3% (provides JulQ update), ABB +4.1%, CHKP +3.5%, REXR +3.4%, SLGN +3.4%, SUM +2.9% (also names new CEO), KEY +2.9%, NDAQ +2.9%, FULT +2.7%, IQV +2.6%, HCSG +2.5%, CSTM +2.5%, BIIB +2.5%, ISRG +1.8%, TXN +1.6%, TMO +1%, NRZ +1%, AVNT +1%, MKTX +0.9%, BRKR +0.8%
Other news:
- PERI +8.8% (to acquire Pub Ocean for up to $22 mln)
- AKCA +8.2% (receives approval for reimbursement of TEGSEDI in Austria for the treatment of hATTR amyloidosis with polyneuropathy) AUPH +7.6% (FDA acceptance of NDA filing for voclosporin)
- LMNX +7.1% (files for Emergency Use Authorization to FDA for expanded NxTAG respiratory panel test including SARS-CoV-2)
- BNTX +6.5% (BioNTech (BNTX) and Pfizer (PFE) reach agreement with the US government for up to 600 mln doses of SARS-CoV-2 vaccine candidate)
- CTSO +6% (prices public offering of 5,263,158 common shares at $9.50/share)
- PFE +5.4% (BioNTech and Pfizer (PFE) reach agreement with the US government for up to 600 mln doses of SARS-CoV-2 vaccine candidate)
- SPOT +4.6% (new multi-year global license agreement with Universal Music Group)
- AGTC +4.3% (announced updated development plans for X-linked retinitis pigmentosa program)
- BBBY +3.9% (BBBY and FLWS reach settlement to complete sale of PersonalizationMall.com)
- KNSA +2.8% (upsizes and prices offering of 5,952,381 common shares at $21.00 per share)
- MESO +2.4% (FDA schedules advisory committee meeting to review data for BLA for RYONCIL)
- APT +2% (Trump says all Americans should wear masks in public places)
- ACI +1.9% (tentative agreement with UFCW unions)
- BSX +1.7% (FDA approval for the WATCHMAN FLX)
- JAZZ +1.4% (receives FDA approval for Xywav oral solution)
Analyst comments:
- CMRE +5.5% (upgraded to Buy from Hold at Stifel)
- VVNT +4.4% (upgraded to Overweight from Neutral at JP Morgan)
- AUTL +3.7% (initiated with a Buy at SunTrust)
- ON +2.9% (upgraded to Buy from Neutral at B. Riley FBR)
- NWN +1.1% (upgraded to Neutral from Sell at UBS)